Telo Financial Statements From 2010 to 2024
| TDSGF Stock | USD 0.08 0 1.23% |
Check Telo Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telo Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Telo financial statements analysis is a perfect complement when working with Telo Genomics Valuation or Volatility modules.
Telo |
Telo Genomics Corp OTC Stock Return On Equity Analysis
Telo Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Telo Genomics Return On Equity | -0.78 |
Most of Telo Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telo Genomics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Telo Genomics Corp has a Return On Equity of -0.7783. This is 96.75% lower than that of the Health Care Technology sector and 88.35% lower than that of the Health Care industry. The return on equity for all United States stocks is 151.06% higher than that of the company.
Telo Genomics Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telo Genomics competition to find correlations between indicators driving Telo Genomics's intrinsic value. More Info.Telo Genomics Corp is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.About Telo Genomics Financial Statements
Telo Genomics stakeholders use historical fundamental indicators, such as Telo Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Telo Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Telo Genomics' assets and liabilities are reflected in the revenues and expenses on Telo Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Telo Genomics Corp. Please read more on our technical analysis and fundamental analysis pages.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo OTC Stock
Telo Genomics financial ratios help investors to determine whether Telo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.